Physician profile
Julius A Gorospe
NPI 1215999842
$10,814.11
in general payments reported to CMS, 2019-2025
55 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $375 · 2021: $1,917 · 2022: $1,825 · 2023: $2,034 · 2024: $1,891 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,862.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,661.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $793.19 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $790.33 | 2021-2025 | |
| Abbott Laboratories | $714.12 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $706.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $684.38 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $519.56 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $504.69 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $447.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $282.61 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Dexcom, INC. | $257.45 | 2021-2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $248.32 | 2021-2025 | |
| Antares Pharma, INC. | $241.62 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.06 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.01 | 2019-2024 | Xifaxan |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $206.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $162.51 | 2023-2025 | Rexulti |
| Globus Medical, INC. | $161.82 | 2025 | Senza |
| Sanofi-Aventis U.S. LLC | $151.25 | 2022-2025 | |
| Eisai INC. | $117.79 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.05 | 2024-2025 | Caplyta |
| Inspire Medical Systems, INC. | $100.13 | 2023-2024 | Inspire |
| Biohaven Pharmaceuticals, INC. | $93.82 | 2021 | |
| Daiichi Sankyo INC. | $87.26 | 2022-2025 | Injectafer |
| Radius Health, INC. | $82.55 | 2025 | |
| Novartis Pharmaceuticals Corporation | $82.54 | 2019-2023 | |
| Insmed, INC. | $80.88 | 2025 | Arikayce |
| Sanofi Pasteur INC. | $60.75 | 2019-2023 | |
| Alk-Abello, INC | $56.52 | 2024-2025 | Grastek, Ragwitek, Odactra |
| Tolmar, INC. | $55.40 | 2024-2025 | Jatenzo |
| Supernus Pharmaceuticals, INC. | $54.34 | 2022-2023 | Xyosted, Tlando, Qelbree |
| Sumitomo Pharma America, INC. | $52.67 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $52.33 | 2020-2021 | |
| Viiv Healthcare Company | $52.09 | 2023-2024 | Apretude |
| Tris Pharma INC | $49.26 | 2023-2025 | Dyanavel Xr |
| Hologic Sales and Service, LLC | $49.14 | 2022-2025 | Aptima |
| Xeris Pharmaceuticals, INC. | $45.82 | 2022 | |
| Axsome Therapeutics, INC. | $44.56 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company Ltd. | $44.11 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $40.52 | 2019-2025 | Austedo Xr |
| Medtronic, INC. | $40.05 | 2023-2025 | Inceptiv, Intellis Adaptivestim |
| Coloplast Corp | $38.42 | 2024 | |
| Jazz Pharmaceuticals INC. | $36.32 | 2021 | |
| Halozyme INC | $35.23 | 2023 | |
| Idorsia Pharmaceuticals US INC | $34.61 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $33.41 | 2024-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $31.75 | 2021-2023 | Seglentis, Livalo |
| Corium, LLC | $27.45 | 2024 | Azstarys |
| Gilead Sciences, INC. | $20.50 | 2019 | |
| Lundbeck LLC | $19.29 | 2024 | Rexulti |
| Allergan, INC. | $19.13 | 2019 | |
| Almatica Pharma LLC | $18.50 | 2024 | Loreev Xr |
| Currax Pharmaceuticals LLC | $15.28 | 2025 | Contrave |
| Nabriva Therapeutics, Plc | $12.92 | 2020 | |
| Shire North American Group INC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Gorospe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.